New combo therapy aims to control advanced liver cancer
NCT ID NCT07587034
First seen May 14, 2026 · Last updated May 14, 2026
Summary
This study tests a new treatment plan for people with intermediate or advanced liver cancer. It combines chemotherapy delivered directly to the liver, a procedure to block the tumor's blood supply, and two drugs (apatinib and camrelizumab) that help the immune system fight cancer. The goal is to see if this combination can slow down the cancer better than current treatments. About 315 adults aged 18-80 with liver cancer that cannot be surgically removed may join.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER CANCER are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.